Post Reply
4301-4320 of 10899
Wah lau, 70 cents already.
It appears tat target price of $1.06 attainable as BB finally catching shorties.
wow... $0.695............... this is a very important resistant point to break...
Ha ha, 7.5 cts up, siow liao. More Carlsbergs loh.
Mostly, this counter is going to get shorted coming monday.
bro, you are back.....
Finally, I see $0.69 again.... not bad ....
novena_33 ( Date: 16-Oct-2009 17:10) Posted:
|
0058 GMT [Dow Jones] STOCK CALL: Nomura initiates Biosensors International (B20.SG) at Buy, sets S$1.06 price target. Broker says the drug-eluting stent (DES) maker moving into phase of sustainable profitability as it comes out of its startup phase. "We see a promising earnings outlook driven by market-share gains in Europe and Asia, accelerating royalties from partner Terumo and significant contribution from its 50%-owned China JV." Says continued momentum in upcoming 2Q10 results, new approvals to market its flagship product BioMatrix in France, China could be potential share price catalysts. Says company is potential acquisition target and in this scenario would be worth more than price target. "Biosensors is a potential M&A target in the medtech space given its next-generation stent technology and valuable DES franchise in China." Shares closed down 0.8% at S$0.61 yesterday. (KIG)
This one is a good boy today...
When others are stagnant, this one moves up... hehehe...
HUAT ARH!!!!!
not so hopeless, start to pick up liao
Hopeless counter,nowonder,Mr bengster not keen anymore
Biosensors, the Singapore-based maker of medical devices such as catheter systems and blood pressure equipment, plans to issue bonds and detachable warrants to refinance maturing debt. A group of 'anchor investors' will buy or find buyers for S$27.5m of 8.5% bonds maturing in three years and 10.6m warrants
Shareholders no need to cough out $$$??
starlene ( Date: 13-Oct-2009 10:34) Posted:
|
Ex price of warrants is 65cts..shd be good,just like Baker Tech after similar announcement..shot above 30cts and remain > 30cts,so Biosensor shd continue to .60cts or even higher near ex-date
JustForFun ( Date: 13-Oct-2009 09:25) Posted:
|
BIOSENSORS : PROPOSED ISSUE OF BONDS AND WARRANTS
Yah, harvest season is coming. Tks for d support, cheers.
Limited downside liao..recent mkt correction drop to ab 58cts then cross over 60cts again...next round when announced good results,will mkae 2009's new high again...expect > support and pushing now that the big shareholders got back their share from JW Medical..surely will not want their BIG to drop again,now that it has climbed to a rspectable 60cts from low of about 23 
<Many long-term supply contracts are based on good relationship rather than BEST product or service. This is especially the case for medical-related products.>
You are absolutely right. R u in this industry?
Many long-term supply contracts are based on good relationship rather than BEST product or service. This is especially the case for medical-related products. That is why so many BEST products are OUTside the mainstreams because they are OUTSIDERs. So many CERTIFIED BEST products are under MLMs.
Just go to any Medicine Shop and ask for general recommendation. The recommendation is NOT the BEST product but the one which gives the vendor the HIGHEST COMMISSION.
There are many cases where cheapest product gives the better cure while the most expensive product makes the patient worst off and may even be damaged or caused to die faster.
Just like CANCER, if one doesn't CHEMO still lives longer. Otherwise, dies fastest.
Following is a Notice Of Cessation Of Substantial Shareholding filed by Biosensors International Group Ltd. with the Singapore Exchange:
StockCode B20
Ref_No 00045
AnnouncedBy BIOSENSORS INT''L GROUP, LTD.
SG_ComRegNo EC 24983
SubmittedFor BIOSENSORS INT''L GROUP, LTD.
SubmittedWrt BIOSENSORS INT''L GROUP, LTD.
AnnouncerName Kevin R. Sayer
Designation Company Secretary
BroadcastDate 08-Oct-2009
BroadcastTime 17:10:53
PriceSensitivity No
ContactNo 6213 5777
SubmissionDate 08/10/2009
SubmissionTime 5:10:15 PM
Following are the announcement details:
DateOfNotice_PartI 08/10/2009
Shareholder_Type_PartI Substantial Shareholder
ShareholderName_PartI JW Medical Limited
NoticeOption_PartI OPTION3
Shareholding_Type_partII -
DateOfChange_partII -
HolderName_partII -
Transaction_Type_partII -
TextAns_details_partII -
InstrumentType_partII -
NumberBeforeChange_partII -
PercentBeforeChange_PartII -
Instrument_Type_partII -
NumberSubject_PartII -
PercentSubject_PartII -
AmtConsideration_PartII -
Instrument_Type_PartII -
NumberAfterChange_PartII -
PercentageAfterChange_PartII -
Shareholding_Type_PartIII Shareholding
DateOfChange_PartIII 06/10/2009
PercentFrom_PartIII 12.16
PercentTo_PartIII 3.80
Transaction_Type_PartIII - Others
TextAns_Details_PartIII JW Medical Limited executed transfers of 88,700,000 shares in the capital of the Company (shares) back to two (2) investors. Following such transfers, JW Medical Limited would have a shareholding interest of 3.80% in the Company.
TextAns_Statement_PartIII The change of the percentage level of interest is the result of the transfers of 88,700,000 shares held by JW Medical Limited back to two (2) investors held in the investment holding company.
Shareholder_Type_PartIV Substantial Shareholder
NumberBefore_Direct 0
NumberBefore_Deemed 129,000,000
PercentBefore_Direct 0
PercentBefore_Deemed 12.16
NumberAfter_Direct 0
NumberAfter_Deemed 40,300,000
PercentAfter_Direct 0
PercentAfter_Deemed 3.80
TextAns_Footnote:
After the above transaction, JW Medical Limited''s total interest in the Company will be 40,300,000 shares held by DB Nominees (S) Pte Ltd, approximately 3.80% of the total issued share capital of the Company. The percentage for "No. of shares held before change" and "No. of shares held after change" is computed based on Biosensors International Group Ltd''s issued share capital of 1,060,725,993 as at 5 October 2009.
Source: Singapore Stock Exchange
Click here to go to Dow Jones NewsPlus, a web front page of today''s most important business and market news, analysis and commentary: http://www.djnewsplus.com/access/al?rnd=GgxXbxoQpFO6b9Z%2BMg3Vuw%3D%3D. You can use this link on the day this article is published and the following day.
(END) Dow Jones Newswires
October 08, 2009 05:11 ET (09:11 GMT)
Novel Polymer-Free Drug Coated Stent Demonstrates Significant Benefit in Efficacy Over Conventional Drug-Eluting Stent With Durable Polymer
San Francisco, USA, 24 September 2009 – Biosensors International Group, Ltd (“Biosensors”, “Company”, BIG:SP) today announced the four-month results from the First-In-Man (“FIM”) trial of BioFreedom™, a novel polymer-free drug-coated stent (“DCS”) which showed a significant reduction in in-stent late lumen loss over Boston Scientific’s TAXUS™ Liberté™ (“TAXUS Liberté”) stent. These results were presented by the Principal Investigator, Professor Eberhard Grube, Helios Heart Center, Siegburg, Germany, as part of the Featured Clinical Trial session at the 21st annual Transcatheter Cardiovascular Therapeutics (“TCT”) scientific symposium, sponsored by the Cardiovascular Research Foundation.
BioFreedom is a new, “polymer-free” Biolimus A9™-coated stent currently under development at Biosensors. Two versions of the product were studied in this trial - BioFreedom Standard Dose (“SD” with a drug dosage of 15.6 μg/ per mm of stent length) and BioFreedom Low Dose (“LD” with a drug dosage of 7.8 μg/ per mm of stent length). Due to the absence of polymer coating, the Company believes that the new stent will promote more rapid vessel healing and reduce the need for longer term anti-platelet medications. The four-month results of the BioFreedom trial have provided proof of concept for this new DCS technology, demonstrating that polymer-free release of an immunosuppressive drug from the abluminal (outside) surface of a porous metal stent is feasible, safe, and can be highly effective in addressing patients with coronary artery disease (“CAD”).
In the recently-completed first cohort of the BioFreedom FIM trial, results demonstrated a significant reduction of in-stent late loss at four months in the two BioFreedom groups (SD and LD) when compared to the TAXUS Liberté group. (BioFreedom SD = 0.08mm vs BioFreedom LD = 0.12 mm vs TAXUS Liberté = 0.37mm, p < 0.0001 & p= 0.002 respectively). In-stent late loss is defined as the amount of tissue that builds up inside the stent months after stent implantation and has long been considered a primary measure of device effectiveness.
An intravascular ultrasound (“IVUS”) analysis of the neointimal tissue volume obstruction, a secondary measure of device effectiveness, was also conducted at four months. This was observed to be 6.6% for the TAXUS Liberté and was significantly lower at 1.3% in the
BioFreedom SD arm (p= 0.0003), while the BioFreedom LD group showed a non-significant reduction (5.5%) in in-stent neointimal tissue volume compared with the TAXUS Liberté.
“The results from BioFreedom FIM are very significant as they demonstrate for the first time that a polymer free drug-coated stent is not only as safe at four months as a conventional drug-eluting stent with a durable polymer coating, but is even more effective at that same time point”, commented Professor Grube. “I am excited about the BioFreedom polymer-free concept as ultimately it may allow us to consider reducing dual anti-platelet therapy duration with patients. However, additional clinical data will be needed to support this approach.”
Mr Mike Kleine, President & CEO of Biosensors added, “With the addition of BioFreedom to our pipeline, we continue to lead the industry in both drug-eluting stent and drug-coated stent innovation. We will continue to invest in new market segments, leveraging our strong technology platform, including our proprietary drug, Biolimus A9.”
BioFreedom FIM is a prospective, multi-centre study. It includes 182 patients who were randomized into three groups. The primary endpoint is in-stent late lumen loss at 12 months, and the major secondary endpoint is in-stent late lumen loss at four months in the first cohort. This first cohort includes 75 patients randomized into three arms: 25 patients in the SD arm, 26 patients in the LD arm and the remaining 24 patients in the TAXUS Liberté control arm.